Back to search

University of Ioannina

Αντιυπερτασική δράση και νεφρο-καρδιαγγειακή προστασία υπερτασικών ασθενών με τη χορήγηση αλισκιρένης

Abstract

dc:description

Inhibition of the renin-angiotensin system (RAS) is a critical approach in the management of arterialhypertension, especially in patients with albuminuria. It is well proven that the direct renin inhibitoraliskiren shows comparable clinical efficacy to the angiotensin II receptor blocker valsartan on bloodpressure control and albuminuria. However, there is only limited data on the effect of these two RAS blockers in improving arterial stiffness. It has been also suggested that aliskiren has a long half-life and maintains a blood pressure lowering effect following a missed dose. Primary aim of this thesis was to investigate whether aliskiren or valsartan could improve arterial stiffness in hypertensive patients with albuminuria who are already on antihypertensive therapy. In addition, we tested the hypothesis that every other day (eod) administration of aliskiren has the same effects as the once daily (od) dosing in albuminuric hypertensive patients. Thirty-four patients with hypertension and albuminuria less than 1000 mg/g, after a washout period, were randomized to aliskiren or valsartan in a 24-week randomized parallel-group study. A nonsignificant difference in blood pressure was seen between the two treatment groups. Albuminuria was significantly reduced in both groups (56% for the aliskiren group, p<0.05, and 38% for the valsartan group, p<0.05). Only valsartan but not aliskiren significantly reduced carotid-femoral pulse wave velocity (–1.1 ± 0.8 m/s (p=0.02) for valsartan and +0.1 ± 0.7 m/s (ns) for aliskiren). No significant difference was found between the groups in arterial stiffness indices after the 24-week treatment period. Thirteen patients from the aliskiren group after the completion of the first 24-week follow up period were switched to an alternate day regime of aliskiren administration for an additional period of 24 weeks. At the end of the study, the 48-h ambulatory BP monitoring was divided into two 24 h periods. The mean 24h systolic BP, and the mean daytime systolic and diastolic BP were significantly lower (P < 0.05) in the first 24h (when aliskiren was administered) compared with the second period. Central hemodynamics showed no significant differences at any time during monitoring. Administration of aliskiren continued to have the same anti proteinuric effect on the alternate day protocol. Differences in plasma renin activity, plasma renin concentration, and aldosterone level measurements were not significant. The results of this study showed that valsartan improves the pulse wave velocity to a greater extent than aliskiren, despite similar antihypertensive and antiproteinuric effect. Overall aliskiren and valsartan appear to have a similar effect on the indices of arterial stiffness. Systematic review of the literature confirms these results. The BP lowering effect of the administration of aliskiren every 48 hours, although adequate, is less efficient compared with once daily administration, despite the fact that in terms of reducing albuminuria, it appears to be effective.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Spanos, Georgios
  • Σπανός, Γεώργιος

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44904

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Spanos, Georgios; Σπανός, Γεώργιος. Αντιυπερτασική δράση και νεφρο-καρδιαγγειακή προστασία υπερτασικών ασθενών με τη χορήγηση αλισκιρένης. University of Ioannina, 2017. http://hdl.handle.net/10442/hedi/44904